NYXH Nyxoah

Information on the total number of voting rights and shares

Information on the total number of voting rights and shares



REGULATED INFORMATION

Information on the total number of voting rights and shares

Mont-Saint-Guibert (Belgium), December 29, 2022, 10:30 pm CET / 4:30 pm ET – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the belowinformation following the issue of new warrants.

  •  Share capital: EUR 4,440,069.16 
  •  Total number of securities carrying voting rights: 25,846,279 (all ordinary shares) 
  •  Total number of voting rights (= denominator): 25,846,279 (all relating to ordinary shares)  
  •  Number of rights to subscribe to securities carrying voting rights not yet issued: 
    •  55 “2016 ESOP Warrants” issued on November 3, 2016, entitling their holders to subscribe to a total number of 27,500 securities carrying voting rights (all ordinary shares); 
    •  100 “2018 ESOP Warrants” issued on December 12, 2018, entitling their holders to subscribe to a total number of 50,000 securities carrying voting rights (all ordinary shares);  
    •  450,500 “2020 ESOP Warrants” issued on February 21, 2020, entitling their holders to subscribe to a total number of 460,500 securities carrying voting rights (all ordinary shares); and
    •  1,350,750 “2021 ESOP Warrants” issued on September 8, 2021, entitling their holders to subscribe to a total number of 1,350,750 securities carrying voting rights (all ordinary shares); and
    •  700,000 “2022 ESOP Warrants” issued on December 28, 2022, entitling their holders to subscribe to a total number of 700,000 securities carrying voting rights (all ordinary shares).  

*

*        *

For further information, please contact:

Nyxoah

Jeremy Feffer, VP IR and Corporate Communications





Attachment



EN
29/12/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Nyxoah

 PRESS RELEASE

Nyxoah Reports Second Quarter Financial and Operating Results

Nyxoah Reports Second Quarter Financial and Operating Results REGULATED INFORMATION Nyxoah Reports Second Quarter Financial and Operating ResultsFDA Approves Genio® System for U.S. Market; Company Begins Commercial Launch Mont-Saint-Guibert, Belgium – August 18, 2025, 10:10pm CET / 4:10 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today reported financial and operating results for the second quarter of 2025. Recent F...

 PRESS RELEASE

Nyxoah Présente ses Résultats Financiers et d’Exploitation pour le Sec...

Nyxoah Présente ses Résultats Financiers et d’Exploitation pour le Second Trimestre 2025 INFORMATIONS RÉGLEMENTÉES Nyxoah Présente ses Résultats Financiers et d’Exploitation pour le Second Trimestre 2025La FDA approuve le système Genio® pour le marché américain ; la Société lance la commercialisation du produit Mont-Saint-Guibert, Belgique – 18 août 2025, 22h10 CET / 16h10 ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (« Nyxoah » ou la « Société »), une société de technologie médicale développant des alternatives thérapeutiques révolutionnaires pour l'apnée obstructive du sommeil (AOS) ...

Jamila El Bougrini ... (+2)
  • Jamila El Bougrini
  • Thibaut Voglimacci-Stephanopoli
 PRESS RELEASE

Nyxoah Announces Preliminary Results for the Second Quarter of 2025

Nyxoah Announces Preliminary Results for the Second Quarter of 2025 Nyxoah Announces Preliminary Results for the Second Quarter of 2025 Mont-Saint-Guibert, Belgium – August 11, 2025, 7:00am CET / 1:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA), today announced certain preliminary, unaudited financial results for the second quarter of 2025 and other business updates.  Preliminary, Unaudited Second Quarter 2025 Financial Results and Business U...

 PRESS RELEASE

Nyxoah Annonce ses Résultats Préliminaires pour le Deuxième Trimestre ...

Nyxoah Annonce ses Résultats Préliminaires pour le Deuxième Trimestre 2025 Nyxoah Annonce ses Résultats Préliminaires pour le Deuxième Trimestre 2025  Mont-Saint-Guibert, Belgique – 11 août 2025, 7h00 CET / 01h00 ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (« Nyxoah » ou la « Société »), une société de technologie médicale développant des alternatives thérapeutiques révolutionnaires pour l'apnée obstructive du sommeil (AOS) par la neuromodulation, a annoncé aujourd'hui certains résultats financiers préliminaires non audités pour le deuxième trimestre 2025 et d'autres informations su...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch